Europe's largest biotech Actelion Ltd (ATLN.VX) was dealt a blow when a jury in a Californian court said Japanese drugmaker Asahi Kasei (3407.T) should be awarded up to $547 million in a licensing dispute. The decision comes at a difficult time for Actelion, which is also under fire from largest shareholder Elliott Advisors and will have to square up to the New York-based hedge fund at its annual general meeting in Basel on Thursday. Here are some key facts about the Actelion vs Asahi case. * Asahi Kasei Pharma Cooperation filed a complaint in the State Court in California against Actelion Ltd and its subsidiaries Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd, Actelion US Holding Company, CoTherix as well as Actelion's chief executive Jean-Paul Clozel, Martine Clozel and Simon Buckingham in November, 2008.
Source
